JP6187939B2 - がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法 - Google Patents

がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法 Download PDF

Info

Publication number
JP6187939B2
JP6187939B2 JP2014503838A JP2014503838A JP6187939B2 JP 6187939 B2 JP6187939 B2 JP 6187939B2 JP 2014503838 A JP2014503838 A JP 2014503838A JP 2014503838 A JP2014503838 A JP 2014503838A JP 6187939 B2 JP6187939 B2 JP 6187939B2
Authority
JP
Japan
Prior art keywords
cells
ssea
cell
cancer
cell population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014503838A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013133220A1 (ja
Inventor
光 上野
光 上野
鈴木　光浩
光浩 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Occupational and Environmental Health Japan
Original Assignee
University of Occupational and Environmental Health Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Occupational and Environmental Health Japan filed Critical University of Occupational and Environmental Health Japan
Publication of JPWO2013133220A1 publication Critical patent/JPWO2013133220A1/ja
Application granted granted Critical
Publication of JP6187939B2 publication Critical patent/JP6187939B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2014503838A 2012-03-08 2013-03-04 がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法 Expired - Fee Related JP6187939B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012052348 2012-03-08
JP2012052348 2012-03-08
PCT/JP2013/055865 WO2013133220A1 (fr) 2012-03-08 2013-03-04 Méthode de test de la malignité du cancer, cellules tumorigènes pluripotentes et procédé de préparation associé

Publications (2)

Publication Number Publication Date
JPWO2013133220A1 JPWO2013133220A1 (ja) 2015-07-30
JP6187939B2 true JP6187939B2 (ja) 2017-08-30

Family

ID=49116697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503838A Expired - Fee Related JP6187939B2 (ja) 2012-03-08 2013-03-04 がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法

Country Status (2)

Country Link
JP (1) JP6187939B2 (fr)
WO (1) WO2013133220A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005230832B2 (en) * 2004-04-01 2010-11-11 Wisconsin Alumni Research Foundation Differentiation of stem cells to endoderm and pancreatic lineage
JP2008278798A (ja) * 2007-05-10 2008-11-20 Tokyo Medical & Dental Univ 膀胱癌の検出方法
US8097407B2 (en) * 2008-01-25 2012-01-17 Hansabiomed Ou Metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression
JP5212977B2 (ja) * 2008-06-10 2013-06-19 国立大学法人福井大学 低酸素培養機器及び無糖培地を用いたがん幹細胞濃縮法
AU2009268937A1 (en) * 2008-06-16 2010-01-14 Aj Park Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
JP2010099039A (ja) * 2008-10-27 2010-05-06 Fujifilm Corp 神経芽腫の検出方法
JP2010130993A (ja) * 2008-12-08 2010-06-17 Bio Matrix Research Inc 乳癌の悪性度の評価方法ならびに該評価方法に用いるアレイおよびキット

Also Published As

Publication number Publication date
JPWO2013133220A1 (ja) 2015-07-30
WO2013133220A1 (fr) 2013-09-12

Similar Documents

Publication Publication Date Title
Kim et al. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression
Thon et al. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas
JP6653689B2 (ja) 癌幹細胞集団及びその作製方法
JP2020073920A (ja) 膵臓がんを診断するための方法
Wang et al. Identification and characterization of CD133+ CD44+ cancer stem cells from human laryngeal squamous cell carcinoma cell lines
EP2529223B1 (fr) Biomarqueurs pour cellules tumorales en circulation
Habu et al. Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma
JP2014506453A (ja) 生得的多能性体細胞
Miconi et al. Immunophenotypic characterization of human glioblastoma stem cells: correlation with clinical outcome
Hopkinson et al. Establishment of a normal-derived estrogen receptor-positive cell line comparable to the prevailing human breast cancer subtype
US9846164B2 (en) Detection of human somatic cell reprogramming
KR101360409B1 (ko) 위암 암 줄기세포 특성에 기초한 위암의 치료용 타겟
JP6990586B2 (ja) デルタ１３３ｐ５３ベータおよびデルタ１３３ｐ５３ガンマアイソフォームはがん幹細胞のバイオマーカーである
US20150017638A1 (en) Methods for assessing risk for cancer using biomarkers
JP6187939B2 (ja) がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法
Mu et al. Human intermediate prostate cancer stem cells contribute to the initiation and development of prostate adenocarcinoma
Zavros et al. Development of Human Pituitary Adenoma Organoids to Facilitate Effective Targeted Treatments of Cushing's Disease.
CN113249476B (zh) 一种影响肿瘤细胞干性的关键蛋白blt2及其应用
Yao et al. Cell-density-dependent manifestation of partial characteristics for neuronal precursors in a newly established human gliosarcoma cell line
Alghezi Identifying potential new stem cell biomarkers for prostate cancer
Utikal et al. Direct transdifferentiation of tumorigenic melanoma cells induces tumor cell reversion
KR102064588B1 (ko) 부갑상선 세포로의 분화 확인용 바이오마커 및 이의 용도
Lefort et al. YB-1 is Required for the Genesis and Metastatic Capacity of Human Breast Cancer
You et al. A new method for obtaining bankable and expandable adult-like microglial cells
Nouri Sox9 mediated reprogramming of prostate cancer cells and acquired therapy resistance

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170612

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170724

R150 Certificate of patent or registration of utility model

Ref document number: 6187939

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees